First National Bank of Omaha Has $2.63 Million Stake in Integra Lifesciences Holdings Corp (IART)

First National Bank of Omaha increased its position in Integra Lifesciences Holdings Corp (NASDAQ:IART) by 2.8% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 39,980 shares of the life sciences company’s stock after purchasing an additional 1,076 shares during the quarter. First National Bank of Omaha’s holdings in Integra Lifesciences were worth $2,633,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently made changes to their positions in IART. Zeke Capital Advisors LLC purchased a new position in shares of Integra Lifesciences in the second quarter valued at $204,000. We Are One Seven LLC purchased a new position in shares of Integra Lifesciences in the third quarter valued at $211,000. Eagle Boston Investment Management Inc. purchased a new position in shares of Integra Lifesciences in the second quarter valued at $223,000. World Asset Management Inc purchased a new position in shares of Integra Lifesciences in the second quarter valued at $261,000. Finally, Zions Bancorporation purchased a new position in shares of Integra Lifesciences in the third quarter valued at $272,000. Institutional investors and hedge funds own 84.82% of the company’s stock.

Several brokerages have recently weighed in on IART. Citigroup decreased their target price on shares of Integra Lifesciences from $66.00 to $60.00 and set a “neutral” rating for the company in a research note on Friday, November 2nd. JMP Securities reduced their price objective on shares of Integra Lifesciences from $66.00 to $62.00 and set a “market outperform” rating on the stock in a research note on Friday, November 2nd. Wells Fargo & Co reduced their price objective on shares of Integra Lifesciences from $61.00 to $55.00 and set a “market perform” rating on the stock in a research note on Thursday, November 1st. Cantor Fitzgerald reduced their price objective on shares of Integra Lifesciences from $59.00 to $54.00 and set a “neutral” rating on the stock in a research note on Thursday, November 1st. Finally, Oppenheimer reiterated a “buy” rating and set a $70.00 price objective on shares of Integra Lifesciences in a research note on Wednesday, October 31st. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating and five have given a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $61.00.

In other Integra Lifesciences news, insider Jeffrey Mosebrook sold 1,000 shares of the stock in a transaction on Friday, August 10th. The shares were sold at an average price of $62.42, for a total transaction of $62,420.00. Following the sale, the insider now directly owns 3,085 shares of the company’s stock, valued at $192,565.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Richard E. Caruso sold 46,676 shares of the stock in a transaction on Wednesday, October 17th. The stock was sold at an average price of $63.19, for a total transaction of $2,949,456.44. Following the sale, the insider now directly owns 134,134 shares in the company, valued at $8,475,927.46. The disclosure for this sale can be found here. Insiders have sold 56,592 shares of company stock worth $3,573,584 over the last three months. 5.10% of the stock is owned by corporate insiders.

NASDAQ IART opened at $55.49 on Wednesday. Integra Lifesciences Holdings Corp has a 12 month low of $45.96 and a 12 month high of $67.50. The company has a debt-to-equity ratio of 1.04, a quick ratio of 2.08 and a current ratio of 3.20. The firm has a market cap of $4.57 billion, a price-to-earnings ratio of 28.60, a P/E/G ratio of 1.69 and a beta of 0.76.

Integra Lifesciences (NASDAQ:IART) last posted its quarterly earnings data on Wednesday, October 31st. The life sciences company reported $0.59 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.59. The firm had revenue of $365.85 million for the quarter, compared to the consensus estimate of $367.89 million. Integra Lifesciences had a net margin of 5.49% and a return on equity of 16.99%. The firm’s revenue was up 31.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.45 EPS. On average, research analysts expect that Integra Lifesciences Holdings Corp will post 2.39 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “First National Bank of Omaha Has $2.63 Million Stake in Integra Lifesciences Holdings Corp (IART)” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/11/07/first-national-bank-of-omaha-has-2-63-million-stake-in-integra-lifesciences-holdings-corp-iart.html.

Integra Lifesciences Company Profile

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.

Featured Story: Terms to Better Understand Call Options

Institutional Ownership by Quarter for Integra Lifesciences (NASDAQ:IART)

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply